|
Registered number:
For the Year Ended
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Touch Medical Media Group Holdings Ltd
Company Information
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Touch Medical Media Group Holdings Ltd
Contents
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Touch Medical Media Group Holdings Ltd
Group Strategic Report
For the Year Ended 31 December 2025
The directors present their Strategic Report for the year ended 31 December 2025.
Touch Medical Media Group is a leading international provider of independent medical education and medical communications. Through its dedicated therapy-area platforms and global network of expert faculty, the Group develops and delivers high-quality, evidence-based medical education across major therapy areas, supporting healthcare professionals worldwide and ultimately contributing to improved patient care.
The Group offers a broad set of integrated services to pharmaceutical (“pharma”) and biopharmaceutical (“biopharma”) via its wholly owned subsidiaries in IME (Touch Independent Medical Education Limited; Touch Independent Medical Education USA LLC, and Touch Independent Medical Education Europe BV – all together, “touchIME”), and Touch Medical Communications Limited (touch-MEDICAL).
The Group also includes a fifth wholly owned subsidiary Touch Medical Media Services Limited (“touchMEDICALMEDIA”), which provides central business support services to the four separate trading companies. The Group has delivered considerable organic growth in recent years, supported by sustained investment in its digital platforms, products, people and operational capabilities. Today, the Group works with support from many of the world’s leading pharmaceutical companies, alongside a growing cohort of innovative biopharmaceutical companies. With truly global reach including Japan and China, and particular strength across the US and Europe, the Group is well positioned to support healthcare professionals across key international markets. The Group utilises an omni-channel approach to maximise the reach and engagement of its medical education among healthcare professionals worldwide. With access to so many different channels, education reaches highly relevant healthcare professional audiences at scale and drives strong levels of engagement with its educational content. 2025 was a successful year for the Group, with increased profitability and further progress in diversifying the business across independent medical education and medical communications. Continued investment in the Group’s product offering, digital capabilities and operational infrastructure, together with improvements in project delivery and efficiency, strengthened the business and created a more scalable platform for future growth. Group EBITDA including realised movement on derivatives increased by 6%, from £752k in 2024 to £799k in 2025, demonstrating the Group’s continued focus on operational efficiency and profitable growth. The Group enters 2026 well positioned to deliver further EBITDA growth. The Group’s improved profitability also contributed to a strengthening of its cash position during the year. Total cash balances reached £1.9 million on 31 December 2025, providing the Group with a strong financial position from which to continue investing in its growth strategy.
Page 1
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Touch Medical Media Group Holdings Ltd
Group Strategic Report (continued)
For the Year Ended 31 December 2025
The Group is exposed to trading risks arising from changes in market conditions, client demand and the timing of project revenues. During 2025, the Group continued to mitigate these risks through disciplined cost management, improvements in project delivery and a continued focus on increasing project margins, resulting in further improvement in gross profitability.
The Group also continued to diversify its product and service offering across independent medical education and medical communications, reducing reliance on any single area of the market and strengthening its overall competitive position. Trading and liquidity risk is further mitigated by the Group’s strong cash position and access to additional loan facilities, providing financial flexibility and cash flow headroom if required. The Group operates within a highly regulated global healthcare environment and is required to comply with strict standards governing medical education. The Group mitigates any risks through robust governance and compliance processes and regular compulsory training. All employees receive regular training on applicable industry codes and regulatory requirements in the markets in which the Group operates, including the ABPI and EFPIA Codes in the UK and Europe and the PhRMA Code in the US, together with relevant country-specific requirements. touchIME maintains relationships with recognised accreditation bodies and accredited providers to ensure that its independent medical education programmes meet the appropriate standards and requirements. touchIME is certified to provide continuing education credits to learners globally and works through joint providership to provide access to credits. The Group is also exposed to inflationary pressures across its cost base. This risk is mitigated through disciplined management of overheads, ongoing operational efficiencies and strong relationships with key suppliers. As an international business, the Group receives a significant proportion of its revenues in US Dollars and Euros while much of its cost base is denominated in Pounds Sterling. The Group is therefore exposed to movements in foreign exchange rates and uses forward currency contracts, where appropriate, to mitigate this exposure and provide greater certainty over budgeting and cash flow.
This report was approved by the board and signed on its behalf.
Page 2
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Touch Medical Media Group Holdings Ltd
Directors' Report
For the Year Ended 31 December 2025
The directors present their report and the financial statements for the year ended 31 December 2025.
The directors are responsible for preparing the Group Strategic Report, the Directors' Report and the consolidated financial statements in accordance with applicable law and regulations.
In preparing these financial statements, the directors are required to:
∙select suitable accounting policies for the Group's financial statements and then apply them consistently;
∙make judgements and accounting estimates that are reasonable and prudent;
∙prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Group will continue in business.
The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the Company's transactions and disclose with reasonable accuracy at any time the financial position of the Company and the Group and to enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Company and the Group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.
The profit for the year, after taxation, amounted to £461,767 (2024 - £310,678).
Dividends paid on equity capital amounted to £889,800 (2024: £216,000). The directors do not recommend the payment of a final dividend.
The directors who served during the year were:
Page 3
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Touch Medical Media Group Holdings Ltd
Directors' Report (continued)
For the Year Ended 31 December 2025
The Group enters 2026 from a strong position, following improved profitability in 2025 and continued progress in strengthening its sales performance, operational efficiency and margins across both touchIME and touchMEDICAL.
Further investment has been made in the business during 2026. This investment is expected to support significant sales growth during 2026 and beyond, while the Group’s increasingly diversified business model provides a strong platform for sustainable, profitable growth. Innovation remains central to the Group’s strategy. Building on its established track record of developing new digital products and educational solutions, the Group has a clear strategy for the adoption of artificial intelligence across its platforms, products and operations. AI will be used to enhance how healthcare professionals discover, access and engage with relevant medical education, while supporting the development of more engaging and personalised learning experiences. The Group will continue to combine technological innovation with expert human insight and high-quality, evidence-based medical education, with the objective of increasing engagement, enhancing clinical knowledge and ultimately contributing to improved patient care.
The directors have referred to their risk management policies in the Group Strategic Report.
There have been no significant events affecting the Group since the year end.
The auditors, Hurst Accountants Limited, will be proposed for reappointment in accordance with section 485 of the Companies Act 2006.
In preparing this report, the directors have taken advantage of the small companies exemptions provided by section 415A of the Companies Act 2006.
This report was approved by the board and signed on its behalf.
Page 4
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Touch Medical Media Group Holdings Ltd
Independent Auditors' Report to the Members of Touch Medical Media Group Holdings Ltd
We have audited the financial statements of Touch Medical Media Group Holdings Ltd (the 'Parent Company') and its subsidiaries (the 'Group') for the year ended 31 December 2025, which comprise the Consolidated Statement of Comprehensive Income, the Consolidated Analysis of Net Debt, the Consolidated Balance Sheet, the Company Balance Sheet, the Consolidated Statement of Cash Flows, the Consolidated Statement of Changes in Equity, the Company Statement of Changes in Equity and the related notes, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).
In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.
Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Group's or the Parent Company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.
Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.
Page 5
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Touch Medical Media Group Holdings Ltd
Independent Auditors' Report to the Members of Touch Medical Media Group Holdings Ltd (continued)
The other information comprises the information included in the Annual Report other than the financial statements and our Auditors' Report thereon. The directors are responsible for the other information contained within the Annual Report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.
We have nothing to report in this regard.
In our opinion, based on the work undertaken in the course of the audit:
∙the information given in the Group Strategic Report and the Directors' Report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
∙the Group Strategic Report and the Directors' Report have been prepared in accordance with applicable legal requirements.
In the light of the knowledge and understanding of the Group and the Parent Company and its environment obtained in the course of the audit, we have not identified material misstatements in the Group Strategic Report or the Directors' Report.
Page 6
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Touch Medical Media Group Holdings Ltd
Independent Auditors' Report to the Members of Touch Medical Media Group Holdings Ltd (continued)
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditors' Report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Group financial statements.
Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:
Identifying and assessing the risks of material misstatement in respect of irregularities In identifying and assessing the risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, we considered the following:
∙The nature of the industry and sector in which the company operates; the control environment and business performance including key drivers for directors' remuneration, bonus levels and performance targets.
∙The outcome of enquiries of local management and parent company management, including whether management was aware of any instances of non-compliance with laws and regulations, and whether management had knowledge of any actual, suspected, or alleged fraud.
∙Supporting documentation relating to the Company's policies and procedures for:
- Identifying, evaluating, and complying with laws and regulations - Detecting and responding to the risks of fraud
∙The internal controls established to mitigate risks related to fraud or non-compliance with laws and regulations.
∙The outcome of discussions amongst the engagement team regarding how and where fraud might occur in the financial statements and any potential indicators of fraud.
∙The legal and regulatory framework in which the Company operates, particularly those laws and regulations which have a direct effect on the financial statements, such as the Companies Act 2006, pensions and tax legislation, or which had a fundamental effect on the operations of the Company, including General Data Protection requirements and Anti-bribery and Corruption.
Audit response to risks identified Our procedures to respond to the risks identified included the following:
∙Reviewing the financial statements disclosures and testing to supporting documentation to assess compliance with the provisions of those relevant laws and regulations which have a direct effect on the financial statements.
∙Discussions with management, including consideration of known or suspected instances of non-compliance with laws and regulations and fraud.
∙Evaluation and testing of the operating effectiveness of management’s controls designed to prevent and detect irregularities.
∙Enquiring of management about any actual and potential litigation and claims.
∙Performing analytical procedures to identify any unusual or unexpected relationships which may indicate risks of material misstatement due to fraud.
Page 7
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Touch Medical Media Group Holdings Ltd
Independent Auditors' Report to the Members of Touch Medical Media Group Holdings Ltd (continued)
We have also considered the risk of fraud through management override of controls by:
∙Testing the appropriateness of journal entries and other adjustments. We have used data analytics software to identify accounting transactions which may pose a heightened risk of material misstatement, whether due to fraud or error.
∙Challenging assumptions made by management in their significant accounting estimates, and assessing whether the judgements made in making accounting estimates are indicative of a potential bias; and
∙Evaluating the business rationale of any significant transactions that are unusual or outside the normal course of business.
We also communicated relevant identified laws and regulations and potential fraud risks to all engagement team members and remained alert to any indications of fraud or non-compliance with laws and regulations throughout the audit. There are inherent limitations in the audit procedures described above, and the further removed non-compliance with laws and regulations are from the events and transactions reflected in the financial statements, the less likely we would become aware of them. Also, the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery or intentional misrepresentations, or through collusion.
A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our Auditors' Report.
This report is made solely to the Company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the Company's members those matters we are required to state to them in an Auditors' Report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Company and the Company's members, as a body, for our audit work, for this report, or for the opinions we have formed.
for and on behalf of
Chartered Accountants & Statutory Auditors
3 Stockport Exchange
SK1 3GG
Page 8
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Touch Medical Media Group Holdings Ltd
Consolidated Statement of Comprehensive Income
For the Year Ended 31 December 2025
Page 9
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Touch Medical Media Group Holdings Ltd
Registered number: 08197142
Consolidated Balance Sheet
As at
The Company's financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.
The financial statements were approved and authorised for issue by the board and were signed on its behalf by:
The notes on pages 16 to 34 form part of these financial statements.
Page 10
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Touch Medical Media Group Holdings Ltd
Registered number: 08197142
Company Balance Sheet
As at
The financial statements were approved and authorised for issue by the board and were signed on its behalf by:
The notes on pages 16 to 34 form part of these financial statements.
Page 11
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Touch Medical Media Group Holdings Ltd
Consolidated Statement of Changes in Equity
For the Year Ended 31 December 2025
Page 12
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Touch Medical Media Group Holdings Ltd
Company Statement of Changes in Equity
For the Year Ended 31 December 2025
Page 13
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Touch Medical Media Group Holdings Ltd
Consolidated Statement of Cash Flows
For the Year Ended 31 December 2025
Page 14
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Touch Medical Media Group Holdings Ltd
Consolidated Analysis of Net Debt
For the Year Ended 31 December 2025
Page 15
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Touch Medical Media Group Holdings Ltd
Notes to the Financial Statements
For the Year Ended 31 December 2025
Touch Medical Media Group Holdings Limited is a private company limited by shares incorporated in England and Wales. The address of the registered office is 3 Stockport Exchange, Stockport, SK1 3GG. The company's registration number is 08197142.
The nature of the group's operations and its principal activities is the publication of learned journals and the provision of medical education. The nature of the company's principal activity is that of a holding company.
2.Accounting policies
The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.
The preparation of financial statements in compliance with FRS 102 requires the use of certain critical accounting estimates. It also requires Group management to exercise judgement in applying the Group's accounting policies (see note 3).
The Company has taken advantage of the exemption allowed under section 408 of the Companies Act 2006 and has not presented its own Statement of Comprehensive Income in these financial statements.
As permitted by FRS 102, the company has not presented its own Statement of cash flows in these financial statements as the cash flows for the company are included in the Consolidated statement of cash flows presented and the net debt reconciliation within the financial statements.
The following principal accounting policies have been applied:
The consolidated financial statements present the results of the Company and its own subsidiaries ("the Group") as if they form a single entity. Intercompany transactions and balances between group companies are therefore eliminated in full.
The consolidated financial statements incorporate the results of business combinations using the purchase method. In the Balance Sheet, the acquiree's identifiable assets, liabilities and contingent liabilities are initially recognised at their fair values at the acquisition date. The results of acquired operations are included in the Consolidated Statement of Comprehensive Income from the date on which control is obtained. They are deconsolidated from the date control ceases. In accordance with the transitional exemption available in FRS 102, the Group has chosen not to retrospectively apply the standard to business combinations that occurred before the date of transition to FRS 102, being 01 January 2014.
Page 16
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Touch Medical Media Group Holdings Ltd
Notes to the Financial Statements
For the Year Ended 31 December 2025
2.Accounting policies (continued)
The financial statements have been prepared on a going concern basis. The following paragraphs set out the basis on which the directors have reached their conclusion.
The Group made a profit before tax of £622k for the year ended 31 December 2025 (2024: £295k). At the balance sheet date, the Group had net current liabilities of £4k (2024: net current assets of £627k). Included within current liabilities is deferred income of £1,894k (2024: £1,775k), representing amounts invoiced in advance of services being provided. Excluding deferred income, the Group remains in a positive working capital position. The Group had net liabilities of £224k at 31 December 2025 (2024: net assets of £204k). The movement to a net liability position arose principally as a result of dividends paid during the year and does not reflect trading losses or adverse operating cash flows. The directors have reviewed cash flow forecasts covering a period of at least 12 months from the date of approval of these financial statements. These forecasts indicate that the Group will have sufficient financial resources to meet its obligations as they fall due. Based on this assessment, the directors have a reasonable expectation that the Group will continue in operational existence for the foreseeable future and have therefore adopted the going concern basis in preparing these financial statements.
Functional and presentation currency
Transactions and balances
Page 17
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Touch Medical Media Group Holdings Ltd
Notes to the Financial Statements
For the Year Ended 31 December 2025
2.Accounting policies (continued)
Page 18
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Touch Medical Media Group Holdings Ltd
Notes to the Financial Statements
For the Year Ended 31 December 2025
2.Accounting policies (continued)
Page 19
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Touch Medical Media Group Holdings Ltd
Notes to the Financial Statements
For the Year Ended 31 December 2025
2.Accounting policies (continued)
Goodwill
Other intangible assets
All intangible assets are considered to have a finite useful life. If a reliable estimate of the useful life cannot be made, the useful life shall not exceed ten years.
The estimated useful lives range as follows:
Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.
Depreciation is provided on the following basis:
The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.
Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.
Page 20
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Touch Medical Media Group Holdings Ltd
Notes to the Financial Statements
For the Year Ended 31 December 2025
2.Accounting policies (continued)
Basic financial assets
Basic financial assets, which include trade and other debtors, cash and bank balances, are initially measured at their transaction price (adjusted for transaction costs except in the initial measurement of financial assets that are subsequently measured at fair value through profit and loss) and are subsequently carried at their amortised cost using the effective interest method, less any provision for impairment, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest.
Discounting is omitted where the effect of discounting is immaterial. The Group's cash and cash equivalents, trade and most other debtors due with the operating cycle fall into this category of financial instruments.
Impairment of financial assets
At the end of each reporting period financial assets measured at amortised cost are assessed for objective evidence of impairment. If an asset is impaired the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset’s original effective interest rate. The impairment loss is recognised in profit or loss.
Financial assets are impaired when events, subsequent to their initial recognition, indicate the estimated future cash flows derived from the financial asset(s) have been adversely impacted. The impairment loss will be the difference between the current carrying amount and the present value of the future cash flows at the asset(s) original effective interest rate.
If there is a favourable change in relation to the events surrounding the impairment loss then the impairment can be reviewed for possible reversal. The reversal will not cause the current carrying amount to exceed the original carrying amount had the impairment not been recognised. The impairment reversal is recognised in the profit or loss.
Page 21
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Touch Medical Media Group Holdings Ltd
Notes to the Financial Statements
For the Year Ended 31 December 2025
2.Accounting policies (continued)
Basic financial liabilities
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Group after the deduction of all its liabilities.
Basic financial liabilities, which include trade and other creditors, bank loans, other loans and loans due to fellow group companies are initially measured at their transaction price (adjusting for transaction costs except in the initial measurement of financial liabilities that are subsequently measured at fair value through profit and loss). When this constitutes a financing transaction, whereby the debt instrument is measured at the present value of the future payments discounted at a market rate of interest, discounting is omitted where the effect of discounting is immaterial.
Debt instruments are subsequently carried at their amortised cost using the effective interest rate method.
Trade creditors are obligations to pay for goods and services that have been acquired in the ordinary course of business from suppliers. Trade creditors are classified as current liabilities if the payment is due within one year. If not, they represent non-current liabilities. Trade creditors are initially recognised at their transaction price and subsequently are measured at amortised cost using the effective interest method. Discounting is omitted where the effect of discounting is immaterial.
Other financial instruments
Derivatives, including forward exchange contracts, futures contracts and interest rate swaps, are not classified as basic financial instruments. These are initially recognised at fair value on the date the derivative contract is entered into, with costs being charged to the profit or loss. They are subsequently measured at fair value with changes in the profit or loss.
Debt instruments that do not meet the conditions as set out in FRS 102 paragraph 11.9 are subsequently measured at fair value through the profit or loss. This recognition and measurement would also apply to financial instruments where the performance is evaluated on a fair value basis as with a documented risk management or investment strategy.
Derecognition of financial assets
Financial assets are derecognised when their contractual right to future cash flow expire, or are settled, or when the Group transfers the asset and substantially all the risks and rewards of ownership to another party. If significant risks and rewards of ownership are retained after the transfer to another party, then the Group will continue to recognise the value of the portion of the risks and rewards retained.
Derecognition of financial liabilities
Financial liabilities are derecognised when the Group's contractual obligations expire or are discharged or cancelled.
Page 22
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Touch Medical Media Group Holdings Ltd
Notes to the Financial Statements
For the Year Ended 31 December 2025
Revenue and margin recognition The group's revenue recognition policies which are set out in note 2.5 are central to how the group values the work it has carried out in each financial year. These policies require assessments and judgements to be made in respect of budgeted versus actual costs. The group reviews, and when necessary, revises the estimates surrounding actual costs as the contracts progress. Following this review, the group deferred income totalling £1,894,061 (2024: £1,774,771). Goodwill Goodwill acquired on business combinations is capitalised on the balance sheet and amortised over its expected useful economic life, or ten years, whichever is shorter. At 31 December 2025 the carrying value of goodwill was £17,734 (2024: £46,706).
Analysis of turnover by country of destination:
Page 23
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Touch Medical Media Group Holdings Ltd
Notes to the Financial Statements
For the Year Ended 31 December 2025
Page 24
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Touch Medical Media Group Holdings Ltd
Notes to the Financial Statements
For the Year Ended 31 December 2025
Page 25
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Touch Medical Media Group Holdings Ltd
Notes to the Financial Statements
For the Year Ended 31 December 2025
11.Taxation (continued)
There were no factors that may affect future tax charges.
Page 26
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Touch Medical Media Group Holdings Ltd
Notes to the Financial Statements
For the Year Ended 31 December 2025
Page 27
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Touch Medical Media Group Holdings Ltd
Notes to the Financial Statements
For the Year Ended 31 December 2025
Page 28
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Touch Medical Media Group Holdings Ltd
Notes to the Financial Statements
For the Year Ended 31 December 2025
Page 29
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Touch Medical Media Group Holdings Ltd
Notes to the Financial Statements
For the Year Ended 31 December 2025
Page 30
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Touch Medical Media Group Holdings Ltd
Notes to the Financial Statements
For the Year Ended 31 December 2025
Page 31
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Touch Medical Media Group Holdings Ltd
Notes to the Financial Statements
For the Year Ended 31 December 2025
Page 32
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Touch Medical Media Group Holdings Ltd
Notes to the Financial Statements
For the Year Ended 31 December 2025
Profit and loss account
The Group operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the Group in an independently administered fund. The pension cost charge represents contributions payable by the Group to the fund and amounted to £235,802 (2024: £195,663). Contributions totalling £31,353 (2024: £23,938) were payable to the fund at the balance sheet date and are included in creditors.
Page 33
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Touch Medical Media Group Holdings Ltd
Notes to the Financial Statements
For the Year Ended 31 December 2025
At 31 December 2025, the company had outstanding loan balances totalling £nil (2024: £360,000) due from a director of the company. The amounts were fully recovered during the year through a combination of cash receipts and the offset of dividends declared.
During the year there was no overall controlling party of Touch Medical Media Group Holdings Limited.
Page 34
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||